DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
QGEN logo

Qiagen N.V. Stock Price

NYSE:QGEN Community·US$8.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 22 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

QGEN Share Price Performance

US$42.50
-5.93 (-12.25%)
​
US$45.28
Fair Value
US$42.50
-5.93 (-12.25%)
6.1% undervalued intrinsic discount
US$45.28
Fair Value
Price US$42.50
AnalystConsensusTarget US$45.28
AnalystLowTarget US$40.11
AnalystHighTarget US$49.47
Fri, 7 Aug 26
Fair ValueUS$45.28
Share Pricen/a

QGEN Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$45.28 6.1% undervalued intrinsic discount

QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery

0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$40.11 6.0% overvalued intrinsic discount

Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$49.47 14.1% undervalued intrinsic discount

Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
QGEN logo
Qiagen
6.1% undervalued intrinsic discount

QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 7 Aug
Read Narrative
QGEN logo
Qiagen
6.0% overvalued intrinsic discount

Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 22 Aug
Read Narrative
QGEN logo
Qiagen
14.1% undervalued intrinsic discount

Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 23 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
QGEN logo

QGEN: Pipeline Progress And Takeover Interest Will Shape Medium Term Outlook

Fair Value: US$40.11 6.0% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
QGEN logo

QGEN: Post Pandemic Testing And Takeover Interest Will Shape Oncology And Diagnostics Outlook

Fair Value: US$45.28 6.1% undervalued intrinsic discount
11 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
QGEN logo

QGEN: Takeover Interest Will Drive Reassessment Of Core Life Science Franchise

Fair Value: US$49.47 14.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet and good value.

1 Risk
2 Rewards
View Full Analysis

Qiagen N.V. Key Details

US$2.1b

Revenue

US$706.0m

Cost of Revenue

US$1.4b

Gross Profit

US$985.0m

Other Expenses

US$409.3m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
1.98
66.38%
19.49%
49.3%
View Full Analysis

About QGEN

Founded
1984
Employees
5500
CEO
Jonathan Pratt
WebsiteView website
www.qiagen.com

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Recent QGEN News & Updates

Recent updates

No updates

Qiagen N.V. Competitors

MRNA logo

Moderna

Symbol: NasdaqGS:MRNA
Market cap: US$56.0b
NTRA logo

Natera

Symbol: NasdaqGS:NTRA
Market cap: US$46.7b
RVMD logo

Revolution Medicines

Symbol: NasdaqGS:RVMD
Market cap: US$44.4b
TEVA logo

Teva Pharmaceutical Industries

Symbol: NYSE:TEVA
Market cap: US$42.8b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide